Treatments for pituitary and adrenal-dependent Cushing s
|
|
- Cecilia Blair
- 5 years ago
- Views:
Transcription
1 Vet Times The website for the veterinary profession Treatments for pituitary and adrenal-dependent Cushing s Author : KAREN CRAWFORD, REBECCA LITTLER Categories : Vets Date : October 6, 2014 KAREN CRAWFORD BVMS, MRCVS REBECCA LITTLER MA, VetMB, PhD, CertSAM, DSAM, MRCVS look at both forms of hyperadrenocorticism, and advise on the importance of determining which form is present before choosing the optimum treatment Summary Cushing s disease, or hyperadrenocorticism (HAC), is one of the most common endocrinopathies in companion animals and is defined as the combination of clinical signs that results from effects of hypercortisolism in the body. Typical clinical signs include polyphagia, polyuria, polydipsia, panting, pot-bellied appearance and dermatological changes. The disease is common in dogs and ferrets and is rarely, though increasingly, recognised in cats. Overproduction of adrenocorticotropic hormone by a small, benign pituitary microadenoma (pituitary-dependent hyperadrenocorticism) is the most common cause of HAC. Less commonly, the condition occurs due to the presence of an adrenal tumour (adrenal-dependent HAC, or ADH). It can be useful to differentiate between the two causes when attempting to select the most appropriate treatment modality. Treatment may be medical or surgical. The treatment method chosen for a dog with HAC depends on several factors, including availability, efficacy, potential side effects, cause and severity of disease, concurrent diseases and the preferences of the client and clinician. Cost of treatment and follow-up evaluation should also be taken into account. 1 / 7
2 Key words hyperadrenocorticism, hypercortisolism, Cushing s, trilostane HYPERADRENOCORTICISM (HAC), also known as Cushing s syndrome, is one of the most common endocrinopathies in companion animals and results from a chronic excess of glucocorticoids. Two spontaneous forms of the disease exist, and the disease may also be iatrogenically induced by administration of exogenous steroids. Overproduction of adrenocorticotropic hormone (ACTH) by a small, benign pituitary microadenoma (pituitary-dependent hyperadrenocorticism or PDH) is the most common cause of HAC. Larger pituitary tumours (pituitary macroadenoma) also occur and can be associated with neurological signs. Less commonly, the condition results from overproduction of cortisol by an adrenal tumour (adrenaldependent HAC or ADH). It can be useful to differentiate between the two causes to give clients a clearer idea of prognosis and likely course of the disease, but also to help select the most appropriate treatment. The treatment method chosen for a dog with HAC depends on several factors, including availability, efficacy, presence of malignancy, potential side effects, cause and severity of disease, concurrent diseases and the preferences of the client and clinician. Cost of treatment and follow-up evaluation should also be taken into account. PDH medical management Trilostane (Vetoryl; Dechra), a synthetic steroid analogue that competitively inhibits steroid synthesis by blocking 3-beta-hydroxysteroid dehydrogenase, is the current licensed treatment for HAC in the UK. Use of trilostane for treatment of canine PDH was first reported in 1998 and several studies have since confirmed its clinical efficacy (Bell et al, 2006; Neiger et al, 2002; Vaughan et al, 2008). Trilostane is available in 10mg, 30mg, 60mg and 120mg capsules. Since it was licensed a number of studies have investigated the safety and efficacy of reducing the initial dose rate. As a result of published literature, which suggests lower starting doses are efficacious and may reduce the risk of side effects, the manufacturer s recommended starting dose has changed to 2mg/kg once daily (previously 3mg/kg to 6mg/kg once daily). Administration of the medication with food is recommended to enhance absorption. Monitoring is carried out based on clinical response and by performing an ACTH stimulation test 2 / 7
3 four to six hours after trilostane administration. Post-ACTH cortisol concentrations of 70nmol/l to 250nmol/l have been suggested to equate to good disease control (Neiger et al, 2002; Vaughan et al, 2008); however, in the authors experience a post-acth cortisol concentration of 40nmol/l to 150nmol/l tends to produce a better effect. The manufacturers recommend monitoring after 10 days, four weeks, 12 weeks, and thereafter every three months, following initial diagnosis and after each dose adjustment. As aldosterone synthesis is also affected (although to a lesser degree than cortisol) by blockade of 3-betahydroxysteroid dehydrogenase, monitoring of serum biochemistry, including electrolytes, is advised. Most owners will notice a reduction in signs such as polyuria/polydipsia in the first 10 days, although other clinical signs, such as skin changes, can take several months to resolve. In the majority of cases, the authors have found it sensible not to increase the trilostane dose at the first recheck, as increasing dosage at this early stage can often lead to development of trilostane overdose. More than half of dogs treated with trilostane will subsequently require some adjustment from their initial starting dose though, with some needing higher or more frequent dosages. The duration of cortisol suppression achieved appears to vary substantially; however, in most dogs cortisol concentrations remained suppressed for less than 13 hours. Even so, good control of the disease can be achieved in a large number of dogs with once daily dosing. Some dogs that do not show satisfactory clinical improvement despite adequate cortisol concentration at peak effect will benefit from twice-daily administration of trilostane. The total daily dose when administering the medication twice daily is generally lower than that required with once daily dosing. Trilostane is well tolerated by most dogs, although minor side effects such as mild lethargy and reduced appetite are sometimes reported transiently. More severe adverse effects, including anorexia, depression, vomiting and diarrhoea, can occur and trilostane has been associated with the development of hypoadrenocorticism. In animals showing such signs, trilostane should be stopped and an ACTH stimulation test performed together with monitoring of haematology, biochemistry and electrolytes. Animals showing signs of an adrenal crisis may require fluid therapy and steroid replacement (glucocorticoids with or without mineralocorticoids), as well as symptomatic treatment with antiemetics and gastroprotectants. Most cases will make a rapid recovery and, once recovery of the adrenal axis has been documented, trilostane can be restarted, although the dose should be reduced by 25 per cent to 50 per cent. Less commonly, reports have documented adrenal necrosis (Chapman et al, 2004) and such animals may require steroid supplementation for life. The most serious complication reported is sudden death (Neiger et al, 2002), and this has occurred in a small number of cases without signs of hypoadrenocorticism; the role of trilostane role in these deaths has not been documented. 3 / 7
4 As HAC is commonly diagnosed in older dogs, concurrent disease processes are often present and these may affect the response to treatment. In particular, diabetes mellitus often occurs concurrently with HAC and HAC is known to lead to insulin resistance. In the majority of cases, controlling HAC will not result in complete resolution of diabetes; however, reducing cortisol levels may increase responsiveness to insulin. Many authors have recommended prospectively reducing insulin dose when starting therapy for HAC, although one study (McLauchlan et al, 2010) showed instigating trilostane treatment was not consistently associated with a reduction in insulin requirement. It is, therefore, possible that reductions in insulin dose at the start of trilostane therapy will not be required in all cases. No specific guidelines exist and the authors advise careful monitoring. Trilostane use is contraindicated in patients with hepatic or renal insufficiency and these cases can pose particular problems. In addition, some patients exhibit severe and/or consistent side effects meaning they are unable to tolerate trilostane therapy. For dogs that do not tolerate trilostane therapy, use of off-licence mitotane, also known as o,p -DDD (Lysodren), which was the treatment of choice prior to the advent of trilostane, may be considered. This drug is an adrenocorticolytic with a direct cytotoxic effect on the adrenal cortex, resulting in selective, progressive necrosis and atrophy. Treatment involves an induction and a maintenance phase and must be monitored closely as side effects are relatively common. Disadvantages of mitotane therapy include its lack of licence, potential for development of irreversible adrenocortical insufficiency, potential drug intolerance, and relatively high frequency of relapse during treatment. Readers are referred to the reference list for suitable treatment protocols. Efficacy of other treatments with either central or peripheral action for treatment of PDH have been investigated (Rijnberk et al, 1988; Peterson and Drucker, 1978; Stolp et al, 1984; Feldman et al, 1998). Ketoconazole, an oral anti-fungal medication, has been shown to inhibit synthesis of glucocorticoids and androgens (Feldman et al, 1998). It effectively lowers circulating cortisol concentrations, but has minimal effect on mineralocorticoids. Ketoconazole has been associated with hepatotoxicity, and for that reason should probably not be considered a suitable alternative therapy for HAC dogs with hepatic insufficiency. Although ketoconazole can control HAC in some dogs, about half of them will fail to respond adequately to treatment (Lien and Huang, 2008) and given the expense, the need for twice-daily dosing and life-long administration, and the lack of efficacy in some cases its use cannot be routinely recommended. Selegiline (L-deprenyl) has also been proposed as an alternative therapy for dogs with HAC. It is thought to work through enhancing dopamine concentration, and thereby down-regulating ACTH secretion. This is probably only effective in dogs where the pituitary tumour arises within the pars intermedia, where ACTH is dependent on dopamine. Most studies have shown little endocrinologic effect, but some clinical improvement (Bruyette et al, 1997; Reusch et al, 1999) and the authors have seen clinical improvement when using this drug for treatment of HAC dogs with renal insufficiency. 4 / 7
5 PDH surgical management Transsphenoidal pituitary surgery is the treatment of choice in people with PDH and hypophysectomy has been described in dogs with PDH (Hanson et al, 2005; Meij et al, 2002). This approach is unlikely to be suitable in all cases and only specialist surgeons with suitable facilities should perform such surgery. Until recently, only one institution in Europe regularly performed this procedure; however, one case has recently been reported at the RVC, making it the first centre in the UK to successfully perform this surgery. PDH managing neurological signs Neurological signs may be noted at any stage during treatment and typically reflect expansion of a pituitary tumour. Commonly seen clinical signs include central blindness, loss of appetite and altered mental alertness. Severity of neurological deficits is a significant prognostic indicator and patients with large intracranial tumours are at increased risk of intracranial haemorrhage or sudden expansion of the tumour following treatment. Advanced imaging (CT or MRI) is required for diagnosis. Radiation therapy can be effective in many cases, although typically the neurological signs improve more rapidly than the endocrinologic signs (Goossens et al, 1998; de Fornel et al, 2007). Radiotherapy does not always result in adequate control of HAC, particularly if the tumour is very large, and medical therapy is often still warranted following radiation treatment. ADH medical management Patients with ADH can potentially be medically managed as for PDH, and medical stabilisation is recommended before considering surgery. In addition, for dogs with inoperable tumours or evidence of metastasis at the time of diagnosis, medical treatment may be appropriate. Mitotane can be used as an adrenocorticolytic in an attempt to control or destroy the adrenal tumour; however, the licensed product, trilostane, has been shown to result in a comparable median survival time (Helm et al, 2011; Arenas et al, 2014) and case reports have described good efficacy in controlling clinical signs of HAC in dogs with ADH. Trilostane is not cytotoxic and therefore will have no effect on growth of the tumour or metastases, but it can be considered a safe and acceptable palliative treatment and, in the authors experience, is generally suitable for medical stabilisation in cases of ADH prior to surgery. Trilostane may be preferable to mitotane for stabilisation prior to surgery as it is less likely to render the tumour more friable. ADH surgical management The ideal treatment for dogs with HAC secondary to a functional adrenocortical tumour is surgical 5 / 7
6 removal of the tumour. This strategy is not without risk, but has the potential for an excellent, and curative, outcome (Kyles et al, 2003; Massari et al, 2011). Preoperative medical stabilisation is generally recommended and probably improves survival. It is important to investigate the extent of local or metastatic spread and to determine the degree of vascular involvement prior to surgery, and advanced imaging is essential for this. Adrenalectomy is technically challenging and a skilled surgeon, together with careful anaesthetic management, is required. Secretion of cortisol from the tumour results in atrophy of the zona fasciculata and zona reticularis. In some dogs the aldosterone producing cells of the zona glomerulosa also atrophy. This means glucocorticoid substitution intraoperatively and postoperatively is required and mineralocorticoid treatment may also be necessary. Where bilateral adrenal tumours are present and bilateral adrenalectomy is required, life-long mineralocorticoid and glucocorticoid replacement is needed. Please note some of the medications mentioned in this article are not licensed. References Arenas C, Melian C and Perez-Alenza M D (2014). Long-term survival of dogs with adrenaldependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment, J Vet Intern Med 28(2): Bell R, Neiger R, McGrotty Y et al (2006). Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotropic hormone in hyperadrenocorticoid dogs, Vet Rec 159(9): Bruyette D S, Ruehl W W, Entriken T et al (1997). Management of canine pituitarydependent hyperadrenocorticism with l-deprenyl (Anipryl), Vet Clin North Am Small Anim Pract 27(2): Chapman P S, Kelly D F, Archer J et al (2004). Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism, J Sm Anim Pract 45(6): de Fornel P, Delisle F, Devauchelle P et al (2007). Effects of radiotherapy on pituitary corticotroph macrotumours in dogs: a retrospective study of 12 cases, Can Vet J 48(5): Feldman E C, Bruyette D S, Nelson R W and Farver T B (1998). Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism, J Am Vet Med Assoc 197(1): Goossens M M, Feldman E C, Theon A P et al (1998). Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism, J Am Vet Med Assoc 212(3): Hanson J M, van t Hoofd M M, Voourhout G, Kooistra H S and Meij B P (2005). Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism, J Vet Intern Med 19(5): Helm J R, McLauchlan G, Boden L, Frowde P E, Collings A J, Tebb A J, Elwood C M, Herrtage M E, Parkin T D and Ramsey I (2011). A comparison of factors that influence 6 / 7
7 Powered by TCPDF ( survival in dogs with adrenal dependent hyperadrenocorticism treated with mitotane or trilostane, J Vet Intern Med 25(2): Kyles A E, Feldman E C, de Cock H E et al (2003). Surgical management of adrenal gland tumours with and without associated tumor thrombi in dogs: 40 cases, J Am Vet Med Assoc 223(5): Lien Y H and Huang H P (2008). Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases, J Am Vet Med Assoc 233(12): 1,896-1,901. Massari F, Nicoli S, Romanelli G et al (2011). Adrenalectomy in dogs with adrenal gland tumours: 52 cases, J Am Vet Med Assoc 239(2): McLauchlan G, Knottenbelt C, Augusto M, McGrotty Y, Helm J and Ramsey I (2010). The effect of trilostane on the insulin requirements and fructosamine concentrations in diabetic dogs being treated for hyperadrenocorticism, J Sm Anim Pract 51(12): Meij B P, Voorhout G, van den Ingh T S G A M et al (1998). Results of transsphenoidal hypophysectomy in 52 dogs with pituitary-dependent hyperadrenocorticism, Vet Surg 27(3): Neiger R, Ramsey I, O Connor J, Hurley K J and Mooney C T (2002). Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism, Vet Rec 150(26): Peterson M E and Drucker W D (1978). Cyproheptadine treatment of spontaneous pituitary ACTH-dependent canine Cushings disease, Clin Res 26: 703A. Reusch C E, Steffen T, Hoerauf A (1999). The efficacy of l-deprenyl in dogs with pituitarydependent hyperadrenocorticism, J Vet Intern Med 13(4): Rijnberk A, Mol J A, Kwant M M and Croughs R J M (1988). J Endocrinol 118(2): Stolp R, Croughs R J M and Rijnberk A (1984). Results of cyproheptadine treatment in dogs with pituitary-dependent hyperadrenocorticism, J Endocrinol 101(3): Vaughan M A, Feldman E C, Hoar B R and Nelson R W (2008). Evaluation of twice daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism, J Am Vet Med Assoc 232(9): 1,321-1, / 7
COMPLICATED CUSHING S CASES AND CONCURRENT CONDITIONS
Vet Times The website for the veterinary profession https://www.vettimes.co.uk COMPLICATED CUSHING S CASES AND CONCURRENT CONDITIONS Author : Gerard Mclauchlan, Ian Ramsey Categories : Vets Date : August
More informationOverview. Clinical signs. Will you treat? Owner willing to treat? Surgical vs. Medical. Medical options
Part II (cushing s disease is hard to diagnose) Cushing s Disease Is Easy To Treat Why test? When to test? How to test? Will you treat? How to treat? Overview Thomas Schermerhorn, VMD, DACVIM(SAIM) Kansas
More informationCompanion Animal TREATMENT: HYPERADRENOCORTICISM (CUSHING S SYNDROME) IN DOGS
Edward C. Feldman, DVM Diplomate ACVIM (SAIM), Professor Emeritus, Small Animal Internal Medicine University of California Davis, California 95616 8737 ecfeldman@ucdavis.edu TREATMENT: HYPERADRENOCORTICISM
More informationA New Approach to Canine Hyperadrenocorticism
A New Approach to Canine Hyperadrenocorticism Jinelle Webb DVM, MSc, DVSc, Diplomate ACVIM Pathophysiology ACTH-secreting pituitary tumour (PDH) Cortisol-secreting adrenal tumour (FAT) Result of both is
More informationCanine hyperadrenocorticism management
SMALL ANIMAL I CONTINUING EDUCATION Canine hyperadrenocorticism management Dr Christine Griebsch DipECVIM-CA, University Veterinary Teaching Hospital Sydney, Australia, discusses management of canine hyperadrenocorticism
More informationHudson, a 10-year-old MC Cocker spaniel, was referred for evaluation of severe polyuria and polydipsia (PU/PD) of 3 months in duration...
VCAWLAspecialty.com David Bruyette, DVM, DACVIM Hudson, a 10-year-old MC Cocker spaniel, was referred for evaluation of severe polyuria and polydipsia (PU/PD) of 3 months in duration... 1. Physical Examination
More informationNaturally occurring hyperadrenocorticism is a wellrecognized
Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism Edward C. Feldman, dvm, dacvim Objective To evaluate effectiveness and
More informationRestore life and vitality in your dog. Feel the same results as an owner.
Restore life and vitality in your dog. Feel the same results as an owner. Your dog, Cushing s syndrome and you This booklet has been designed to help answer questions that you may have about Cushing s
More informationHyperadrenocorticism: Diagnosis and Treatment
Hyperadrenocorticism: Diagnosis and Treatment Jinelle Webb DVM, MSc, DVSc, Diplomate ACVIM Pathophysiology ACTH-secreting pituitary tumour (PDH) Cortisol-secreting adrenal tumour (FAT) Result of both is
More informationRestore life and vitality in your dog. Feel the same results as an owner.
Restore life and vitality in your dog. Feel the same results as an owner. Your dog, Cushing s syndrome and you This booklet has been designed to help answer questions that you may have about Cushing s
More informationCanine Cushings Syndrome: Diagnostic Approaches and Treatment Options
Canine Cushings Syndrome: Diagnostic Approaches and Treatment Options Jinelle Webb DVM, MSc, DVSc, Diplomate ACVIM Pathophysiology ACTH-secreting pituitary tumour (PDH) Cortisol-secreting adrenal tumour
More information(trilostane) What is Cushing s Syndrome?
(trilostane) What is Cushing s Syndrome? T E C H N I C A L B R O C H U R E What is Cushing s Syndrome? Hyperadrenocorticism, or Cushing s syndrome, is one of the most commonly diagnosed canine endocrine
More informationSpontaneous hyperadrenocorticism (HAC) is one of the
J Vet Intern Med 2005;9:80 85 A Comparison of the Survival Times of Dogs Treated with Mitotane or Trilostane for Pituitary-Dependent Hyperadrenocorticism E.N. Barker, S. Campbell, A.J. Tebb, R. Neiger,
More informationReview article SELECTING THE BEST TREATMENT OPTION FOR A DOG WITH CUSHING`S SYNDROME. GALAC Sara INTRODUCTION
Review article Acta Veterinaria-Beograd 2015, 65 (1), 1-19 UDK: 636.7.09:616.453-008.84-08 DOI: 10.1515/acve-2015-0001 SELECTING THE BEST TREATMENT OPTION FOR A DOG WITH CUSHING`S SYNDROME GALAC Sara Dept.
More informationTreat their Cushing s Syndrome. Help restore their vitality. Dechra Veterinary Products April 2015
Treat their Cushing s Syndrome. Help restore their vitality. www.dechra-us.com Dechra Veterinary Products April 2015 Dechra Veterinary Products US and the Dechra D logo are registered trademarks of Dechra
More informationFederal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
USA Product Label http://www.vetdepot.com DECHRA VETERINARY PRODUCTS Distributed by DECHRA VETERINARY PRODUCTS 7015 COLLEGE BLVD., STE. 525, OVERLAND PARK, KS, 66211 Telephone: 913-327-0015 Toll-Free:
More informationSpontaneous hyperadrenocorticism (HAC) is a consequence
J Vet Intern Med 2014;28:481 487 Clinical Findings, Diagnostic Test Results, and Treatment Outcome in Cats with Spontaneous Hyperadrenocorticism: 30 Cases S.Y. Valentin, C.C. Cortright, R.W. Nelson, B.M.
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS (Reference Member State) DECENTRALISED PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL
More informationSpontaneous hyperadrenocorticism (HAC) is a
Standard Article J Vet Intern Med 2016;30:1637 1641 Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism C. Aldridge, E.N. Behrend, R.J. Kemppainen,
More informationMonitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations
ttp://www.bsava.com/ PAPER Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations BACKGROUND: Acute phase proteins (APPS) include
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS (Reference Member State) MUTUAL RECOGNITION PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS (Reference Member State) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
More informationComparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane
Boretti et al. BMC Veterinary Research (2018) 14:417 https://doi.org/10.1186/s12917-018-1750-3 RESEARCH ARTICLE Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with
More informationDeposited on: 07 June 2010
Arteaga, A. and Dhand, N.K. and McCann, T. and Knottenbelt, C.M. and Tebb, A.J. and Evans, H. and Eckersall, P.D. and Ramsey, I.K. (2010) Monitoring the response of canine hyperadrenocorticism to trilostane
More informationCanine Cushing s Case Files: The ins and outs of detection and
Canine Cushing s Case Files: The ins and outs of detection and treatment 01CS-VET0001-0615 Sponsored by Dechra Veterinary Products Canine Cushing s Case Files: The Ins and Outs of Detection and Treatment
More informationPituitary-dependent hyperadrenocorticism in a shi tzu dog treated with twice-daily oral trilostane: a case report
DOI: 10.5433/1679-0359.2012v33n5p1937 Pituitary-dependent hyperadrenocorticism in a shi tzu dog treated with twice-daily oral trilostane: a case report Hyperadrenocorticismo hipófise dependente em um cão
More informationDiagnosis of hyperadrenocorticism (HAC) in the
J Vet Intern Med 2012;26:945 952 Concentrations of Noncortisol Adrenal Steroids in Response to ACTH in Dogs with Adrenal-Dependent Hyperadrenocorticism, Pituitary-Dependent Hyperadrenocorticism, and Nonadrenal
More informationSINGLE ANNUAL IMPLANT
Manage pet ferret adrenal cortical disease with a SINGLE ANNUAL IMPLANT NOT APPROVED BY FDA Legally marketed as an FDA Indexed Product under MIF 900-013. FOR USE IN FERRETS ONLY. Extra-label use is prohibited.
More informationChapter 2. General introduction
Chapter 2 General introduction General introduction Hyperadrenocorticism in ferrets is thought to be primarily of adrenal origin. This introduction will provide an overview of current knowledge on adrenocortical
More informationEQUINE CUSHING S DISEASE
EQUINE CUSHING S DISEASE (PPID) The facts What is Equine Cushing s Disease? Equine Cushing s Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is a common condition affecting older horses
More informationChristie Ward - The Question of Cushings
Many horse people are familiar with the classical symptom of advanced Cushing's disease in horses: a shaggy coat that refuses to shed out in the spring. But did you know that this hormonal disease can
More informationGranulosa Cell Tumor Associated with Occult Hyperadrenocorticism in a Yorkshire Terrier Bitch
Acta Scientiae Veterinariae, 2018. 46(Suppl 1): 320. CASE REPORT Pub. 320 ISSN 1679-9216 Granulosa Cell Tumor Associated with Occult Hyperadrenocorticism in a Yorkshire Terrier Bitch Priscilla Deluchi¹,
More informationA flexible, reversible alternative to surgical castration
Vet Times The website for the veterinary profession https://www.vettimes.co.uk A flexible, reversible alternative to surgical castration Author : Virbac Categories : Canine, Companion animal, General,
More informationAmerican Association of Feline Practitioners American Animal Hospital Association
American Association of Feline Practitioners American Animal Hospital Association Basic Guidelines of Judicious Therapeutic Use of Antimicrobials August 1, 2006 Introduction The Basic Guidelines to Judicious
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationIndicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Zoetis UK Limited Telephone: 0845 300 8034 Website: www.zoetis.co.uk Email: customersupportuk@zoetis.com Apoquel film-coated for dogs Species: Therapeutic indication: Active ingredient: Product: Product
More informationHealth Products Regulatory Authority. Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Dexa-ject 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Per ml: Active substance: Dexamethasone
More informationDEVELOPMENTS IN DIAGNOSIS AND TREATMENT OF CUSHING S DISEASE
Vet Times The website for the veterinary profession https://www.vettimes.co.uk DEVELOPMENTS IN DIAGNOSIS AND TREATMENT OF CUSHING S DISEASE Author : Jo Ireland Categories : Vets Date : May 28, 2012 Jo
More informationAssociated Terms: Breast Cancer, Radical Mastectomy, Mastectomy, Mammectomy, Mammary Adenocarcinoma
Associated Terms: Breast Cancer, Radical Mastectomy, Mastectomy, Mammectomy, Mammary Adenocarcinoma The term "ACVS Diplomate" refers to a veterinarian who has been board certified in veterinary surgery.
More informationNEW In-Clinic Instrument Range Package Now Available
ASAP LABORATORY NEWS FEBRUARY 2015 Hi everyone Please find below the latest ASAP news. NEW In-Clinic Instrument Range Package Now Available ASAP is pleased to announce the launch of a collaboration with
More informationAustralian and New Zealand College of Veterinary Scientists. Fellowship Examination. Small Animal Surgery Paper 1
Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2016 Small Animal Surgery Paper 1 Perusal time: Twenty (20) minutes Time allowed: Three (3) hours after perusal Answer
More informationBEHAVIOURAL OR MEDICAL? ANXIETY DISORDERS IN OLDER ANIMALS. Dr Kersti Seksel BVSc (Hons), MRCVS, MA (Hons), FACVSc, DACVB, CMAVA, DECVBM-CA
BEHAVIOURAL OR MEDICAL? ANXIETY DISORDERS IN OLDER ANIMALS Dr Kersti Seksel BVSc (Hons), MRCVS, MA (Hons), FACVSc, DACVB, CMAVA, DECVBM-CA Registered Veterinary Specialist in Behavioural Medicine www.sabs.com.au
More informationAmerican Ferret Association, Inc. PO Box 554 Frederick, MD FERRET-1
American Ferret Association, Inc. PO Box 554 Frederick, MD 21705-0554 1-888-FERRET-1 afa@ferret.org www.ferret.org ADRENAL DISEASE IN FERRETS Renee Gandolfi, DVM, ABVP Dipl. Castro Valley Companion Animal
More informationXournals. Xournals. A Study on Addison s Disease in Dogs. Ritu Kumari 1. Abstract: Authors:
ISSN UA Volume 01 Issue 01 January-2019 A Study on Addison s Disease in Dogs Ritu Kumari 1 Available online at: www.xournals.com Received 19 th September 2018 Revised 16 th October 2018 Accepted 18 th
More informationTreatment of septic peritonitis
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Treatment of septic peritonitis Author : Andrew Linklater Categories : Companion animal, Vets Date : November 2, 2016 Septic
More informationAdrenal Cortical Carcinomas with Myxoid Differentiation in Ferrets
Adrenal Cortical Carcinomas with Myxoid Differentiation in Ferrets M. Kiupel,, R.A. Peterson II, C.C. Capen,, D.B. Wilson 4125 Beaumont Road Lansing, MI 48910 www.animalhealth.msu.edu Signalment 5-year-old
More informationAustralian and New Zealand College of Veterinary Scientists. Fellowship Examination. Small Animal Medicine Paper 1
Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2015 Small Animal Medicine Paper 1 Perusal time: Twenty (20) minutes Time allowed: Four (4) hours after perusal Answer
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationFACT OR FICTION? DISPELLING MYTHS OF RABBIT NEUTERING
Vet Times The website for the veterinary profession https://www.vettimes.co.uk FACT OR FICTION? DISPELLING MYTHS OF RABBIT NEUTERING Author : Glen Cousquer Categories : RVNs Date : December 1, 2009 Glen
More informationDECISION AND SECTION 43 STATEMENT TO THE VETERINARY COUNCIL BY THE COMPLAINTS ASSESSMENT COMMITTEE: CAC Dr Alfa 1. Complaint from Miss Bravo
DECISION AND SECTION 43 STATEMENT TO THE VETERINARY COUNCIL BY THE COMPLAINTS ASSESSMENT COMMITTEE: CAC16-26 Introduction Dr Alfa 1 Complaint from Miss Bravo 1. A Complaints Assessment Committee (CAC)
More informationElanco Osurnia US. New Case - Pet Owner
Elanco Osurnia US New Case - Pet Owner Elanco Osurnia US Recheck - Pet Owner Elanco Osurnia US Recurring - Pet Owner 617786 USA 921849 Otic gel Antibacterial, antifungal, anti-inflammatory For Otic Use
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg
More informationAPOQUEL 3.6 MG TABLETS FOR DOGS / KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING
Product Name: APVMA Approval No: APOQUEL 3.6 MG TABLETS FOR DOGS 68311 / 115483 Label Name: APOQUEL 3.6 MG TABLETS FOR DOGS Signal Headings: PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR
More informationFrequently asked questions
Frequently asked questions At what stage of heart failure should Cardalis be used? Cardalis should be given as part of your standard heart failure therapy as soon as clinical signs (such as exercise intolerance,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationMedical Conditions Questionnaire
Medical Conditions Questionnaire (to be completed by the member) Member Full Name.Date of birth. Policy number or scheme name. Please complete the appropriate section(s) only after completing the Member
More informationPathogenesis and treatment of feline lower urinary tract disease
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Pathogenesis and treatment of feline lower urinary tract disease Author : Sarah Caney Categories : RVNs Date : May 1, 2011
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationCopper-Storage Liver Disease Basics
Copper-Storage Liver Disease Basics OVERVIEW Abnormal accumulation of copper in the liver, causing sudden (acute) inflammation of the liver (hepatitis) or long-term (chronic) hepatitis and eventually progressive
More informationCOLLEGE OF VETERINARY MEDICINE
Title: A randomized, masked, placebo controlled field study to determine efficacy and safety of Paccal Vet in dogs with non resectable (or unresected) mammary carcinoma of stage III-V 1. Why is the study
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationAcute Pyelonephritis POAC Guideline
Acute Pyelonephritis POAC Guideline Refer full regional pathway http://aucklandregion.healthpathways.org.nz/33444 EXCLUSION CRITERIA: COMPLICATED PYELONEPHRITIS Discuss with relevant specialist for advice
More informationFemale reproductive emergencies approaches to pyometra treatment
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Female reproductive emergencies approaches to pyometra treatment Author : Daniel Forster Categories : Vets Date : May 2, 2011
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10988/066/001 Case No: 7004829 The Irish Medicines Board in exercise of the powers conferred
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationMedicine / Pharmaceuticals CATALOGUE
Medicine / Pharmaceuticals CATALOGUE YOUR COMPLETE VETERINARY SUPPLY AND SUPPORT SOLUTION Cats / 250mg x 100 tablets 500mg x 100 tablets CLAVET TABLETS E000973 E000981 Indicated for the treatment of infections
More informationEffects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism
Sieber-Ruckstuhl et al. BMC Veterinary Research (217) 13:279 DOI 1.1186/s12917-17-1187- RESEARCH ARTICLE Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism
More informationPain Management in Racing Greyhounds
Pain Management in Racing Greyhounds Pain Pain is a syndrome consisting of multiple organ system responses, and if left untreated will contribute to patient morbidity and mortality. Greyhounds incur a
More informationEvaluation of a Urine Cortiso1:Creatinine Ratio as a Screening Test for Hyperadrenocorticism in Dogs
Evaluation of a Urine Cortiso1:Creatinine Ratio as a Screening Test for Hyperadrenocorticism in Dogs Laura E. Smiley, DVM, and Mark E. Peterson, DVM The authors collected urine specimens in 31 normal dogs,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationIs Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process?
Is Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process? A Knowledge Summary by Adam Swallow BVSc MRCVS 1* 1 University of Bristol * Corresponding
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DEXAMECINE 2 mg/ml solution for injection for cattle, horses, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationUpdate of Ferret Adrenal Disease: Etiology, Diagnosis, and Treatment
Update of Ferret Adrenal Disease: Etiology, Diagnosis, and Treatment Cathy A. Johnson-Delaney, DVM, Dipl ABVP (Avian) Session #135 Affiliation: From Eastside Avian & Exotic Animal Medical Center, PLLC,
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10988/081/002 Case No: 7007872 The Irish Medicines Board in exercise of the powers conferred
More informationPain management: making the most of the latest options
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Pain management: making the most of the latest options Author : James Westgate Categories : Business, Business planning Date
More informationTreatment of canine generalized demodicosis associated with hyperadrenocorticism with spot-on moxidectin and imidacloprid
Huang and Lien Acta Veterinaria Scandinavica 2013, 55:40 BRIEF COMMUNICATION Open Access Treatment of canine generalized demodicosis associated with hyperadrenocorticism with spot-on moxidectin and imidacloprid
More informationOutline Animal Welfare Series Caring for the Senior Pet
Outline Animal Welfare Series Caring for the Senior Pet Joshua Steinhaus Christie Wong Veterinary Specialty Hospital (VSH)- Hong Kong What is an older patient? Defining Age Defining Geriatric Medicine
More informationCOMPARATIVE RESPONSE OF BLOOD CORTISOL LEVELS TO TWO DIFFERENT DOSES OF INTRAVENOUS ACTH (TETRACOSACTRIN) IN OVERWEIGHT CATS. Johannes Petrus Schoeman
COMPARATIVE RESPONSE OF BLOOD CORTISOL LEVELS TO TWO DIFFERENT DOSES OF INTRAVENOUS ACTH (TETRACOSACTRIN) IN OVERWEIGHT CATS by Johannes Petrus Schoeman Submitted in partial fulfilment of the requirements
More informationWhat dose of methadone should I use?
What dose of methadone should I use? Professor Derek Flaherty BVMS, DVA, DipECVAA, MRCA, MRCVS RCVS and European Specialist in Veterinary Anaesthesia SPC dose rates for Comfortan dogs: 0.5-1.0 mg/kg SC,
More informationAvoiding anaesthesia related complaints
Veterinary Practitioners Board OF NEW SOUTH WALES Avoiding anaesthesia related complaints John Baguley BVSc MBA PhD GradCert(HigherEd) MANZCVS MAICD Outline 1. Overview of complaints 2. General principles
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationTRIAMCINOLONE ACETONIDE-
TRIAMCINOLONE ACETONIDE- triamcinolone acetonide ointment Perrigo New York Inc ---------- Triamcinolone Acetonide Ointment USP, 0.025%, 0.1%, 0.5% For Dermatologic Us e Only Not For Ophthalmic Us e Rx
More informationPROTOCOL FOR THE HUMANE CARE AND USE OF LIVE VERTEBRATE ANIMALS
PROTOCOL FOR THE HUMANE CARE AND USE OF LIVE VERTEBRATE ANIMALS Federal animal welfare regulations require that the Institutional Animal Care and Use Committee (IACUC) must review and approve all activities
More informationClinical Programme. Dermatology
2018 The diagnosis and management of skin represents a major component of small animal practice. Through lectures, case discussions and practical sessions, this modular programme will enable you to learn
More informationEar drops suspension. A smooth, uniform, white to off-white viscous suspension.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg tablets for dogs Cardalis 5 mg/40 mg tablets for dogs Cardalis 10 mg/80 mg tablets for dogs
More informationUnshakeable confidence
NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationPrimates: Cercopithecidae
Primates: Cercopithecidae Fact Sheet Compiled by: Yedra Feltrer MSc MRCVS ZSL veterinary officer Last Updated: March 2014 Fact Sheet Reviewed by: Sally Boutelle MS Contraceptive methods: GnRH agonist (implant)
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cardalis 2.5 mg/20 mg chewable tablets for dogs Cardalis 5 mg/40 mg chewable tablets for dogs Cardalis 10 mg/80
More informationStaphylex Flucloxacillin (sodium)
Staphylex Flucloxacillin (sodium) PRODUCT INFORMATION Name of the Medicine Flucloxacillin sodium is the sodium salt of 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isoxazolylpenicillin monohydrate. Structural
More informationClinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease
Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease Robert A. Wagner, VMD; Claude A. Piché, DVM, MSc; Wolfgang Jöchle, DVM, Dr Med Vet;
More information